

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 76264

Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05429043

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Greece

Manuscript submission date: 2022-03-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-11 08:53

Reviewer performed review: 2022-03-11 10:45

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The article is very interesting, but I have a few concerns 1. The title should be specific for oncologic malignancies, It is better to mention separately pre-clinical evidence and clinical evidence for each type of formulation. The abstract can be included with details of type of formulation mentioned in the content. The graphical extract will be helpful for understanding the content. Not found any details on liver cancer based formulation in the table or content?

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 76264

Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06275113

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2022-03-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-11 02:09

Reviewer performed review: 2022-03-21 07:48

Review time: 10 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Overall the article lack a main logistic flow. The title clearly state “nanomedicine”, but a considerable portion of the article describes immunotherapy and checkpoint blockade therapy, give an impression of lack of focus. The entire immune checkpoint inhibitor section appeared had no relevance with nonamedicine. The NK cell section included CAR-T therapy, which seems mixed content. At least, the concept of nanomedicine needs a clear definition in the beginning. Introduction section, first paragraph, the last sentence, “ultimately hindering the cell cycle”, hindering cell cycle? Please explain.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 76264

Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05429043

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Greece

Manuscript submission date: 2022-03-09

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2022-06-07 05:29

Reviewer performed review: 2022-06-07 06:44

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Please upload the figures. Now the file uploaded is manuscript file